Engflag

Karazepin

Quick links to important sections

Karazepin

Karazepin_EN

Method of action: Analgesic, Analgetic, Anticonvulsant, Antidepressant, Antiepileptic, Antipsychotic, Normotimical, Sedative

Treatment option: Ataxia, Pain, Generalized Seizures, Depressive Psychosis, Dysarthria, Neuralgia, Trigeminal Neuralgia, Seizure, Fits, Psychosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Karazepin

Property Description
Active ingredient Carbamazepine
Form Tablet (Standard/XR), Capsule (XR), Oral Suspension
Pharmacological class Anticonvulsant, Mood Stabilizer
Common purpose Stabilizing abnormal nerve cell activity
Origin Synthetic (Dibenzoazepine structure)

Karazepin is the trade name for the prescription medicine containing the synthetic compound Carbamazepine, its sole active ingredient. It is primarily categorized pharmacologically as an anticonvulsant belonging to the dibenzazepine chemical group. Research confirms Carbamazepine's efficacy in controlling neuronal excitability, supporting the medicine's role in helping manage conditions involving overly active nerve signals.

What Type of Medicine is Karazepin?

Karazepin is classified as a core anticonvulsant and is also recognized for its use as a mood-stabilizing agent. The active substance, Carbamazepine, is a synthetic organic compound and is structurally related to tricyclic antidepressants, a feature that helps explain its effectiveness across both neurological hyperexcitability and certain nerve pain disorders. Its established use as a primary treatment for partial onset seizures in the USA and Europe has been clinically recognized for many years.

Composition and Available Forms of Karazepin

The medication's therapeutic effect relies exclusively on the active ingredient, Carbamazepine, which is prepared for oral administration. Carbamazepine is available as standard immediate-release tablets, an oral suspension, and specialized extended-release (XR) versions, such as tablets and capsules. This range of oral forms, including the XR variants, is crucial for maintaining stable drug levels in the body.

Karazepin’s High-Level Purpose

The general purpose of Karazepin is to promote a stable electrical environment within nerve cells. Carbamazepine achieves this by functioning as a potent sodium channel blocker. By binding to voltage-gated sodium channels, it limits the ability of nerve cells to repeatedly generate and propagate rapid electrical impulses. This membrane-stabilizing action serves the primary therapeutic goal of regulating neurological excitability and promoting a controlled state of nerve function.

Regulatory References

  1. NIH StatPearls: Carbamazepine
  2. NIH StatPearls: Sodium Channel Blockers

What side effects are possible with Karazepin?

Possible side effects and safety information

The safety profile of Karazepin is categorized by regulatory bodies based on the frequency and system-organ class affected by adverse reactions. The most frequently documented effects, classified as very common, include nervous system disorders such as dizziness, somnolence (drowsiness), and ataxia, along with nausea and vomiting. These common effects often appear at the beginning of treatment and may lessen over time.

Adverse effects are also categorized by the physiological system involved, including effects on the Blood and Lymphatic System (e.g., leukopenia, thrombocytopenia), Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders.

The medicine's regulatory labeling includes warnings for several serious adverse reactions. These include severe, potentially fatal skin reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are most likely to occur in the first few months of use. Serious blood disorders, notably aplastic anemia and agranulocytosis, are also documented as rare but significant risks. A small increased risk of suicidal behavior and ideation is recognized across the class of anti-epileptic drugs.

Specific safety considerations exist for certain populations. Patients of Asian ancestry should be screened for the *HLA-B1502 allele, as its presence is strongly associated with an increased risk of SJS/TEN. The use of this medicine is contraindicated in individuals with a history of bone marrow depression. Additionally, it is associated with embryofetal toxicity** and can decrease the effectiveness of hormonal contraceptives.

Overdose and Emergency Response

Overdose involving Karazepin (Carbamazepine) is characterized by a specific profile of manifestations documented in regulatory information. The most significant effects involve the Central Nervous System, presenting as somnolence, confusion, ataxia, nystagmus, dysarthria, and the risk of generalized seizures or progression to coma.

Life-threatening outcomes are associated with the drug's effects on the Cardiovascular System, where overdose may cause significant cardiac conduction disturbances (QRS complex widening) leading to severe arrhythmias and profound hypotension. Respiratory function is also impacted, with a risk of respiratory depression and respiratory arrest. Regulatory documents also cite physiological findings such as hyponatraemia and hypothermia.

Any suspected overdose necessitates seeking immediate medical attention and requires admission to hospital for observation. The official management is explicitly symptomatic and supportive, as no specific antidote is known for this toxicity. Management protocols mandated by regulators include continuous cardiac monitoring (ECG) and the use of procedures like gastric lavage and activated charcoal to reduce absorption. For severe cases, enhanced elimination techniques may be required. Furthermore, the official labeling indicates that children require special consideration for observation due to the potential for a delayed onset of symptoms.

Therapeutic Uses of Karazepin

What Karazepin Treats: Main Uses and Benefits

Karazepin is commonly used in managing conditions characterized by symptoms related to heightened physiological activity and pronounced symptomatic discomfort. The medicine is considered relevant for easing symptom clusters that may become intense or disruptive and symptoms associated with acute or episodic changes.

It is applied across therapeutic domains including: epilepsy (focal and generalized tonic-clonic seizures), trigeminal neuralgia (symptoms related to physical discomfort and episodic facial nerve pain), and Bipolar I Disorder (managing acute manic and mixed episodes).

The medication assists in situations where symptoms interfere with daily functioning, such as during phases of increased distress or discomfort. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when these symptoms interfere with routine activities. It may also help patients cope more steadily with symptom fluctuations relevant in conditions characterized by periods of heightened symptoms.

Quick Fact: Relief for Episodic Discomfort Karazepin is commonly used when short-term symptomatic assistance is needed for recurrent, unpredictable symptom patterns in both neurological and psychiatric contexts, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Official Eligibility Status by Population

Karazepin (Carbamazepine) eligibility is defined by regulatory authorities based on pre-existing conditions and patient demographics.

Eligibility Classification Population / Condition
Absolutely Contraindicated History of bone marrow depression or hepatic porphyrias
Known hypersensitivity to Carbamazepine or tricyclic compounds
Concomitant use with MAO Inhibitors (within 14 days)
Restricted/Conditional Use Patients with specific Asian ancestry must be screened for the *HLA-B1502 allele**. Use is not recommended if positive unless the clinical benefit clearly outweighs the high risk of serious skin reactions.
Pre-existing hepatic, renal, or cardiac damage requires critical risk-benefit appraisal and close monitoring.
Use during pregnancy is restricted to cases where the benefit justifies the fetal risk. The drug is excreted into breast milk, requiring a careful risk assessment.
Age-Related Status Use is established for children (typically starting at age 6) for certain seizure types. Older adults may be at a greater risk for conditions like hyponatremia and require caution.
Formulation Restriction The oral suspension formulation is contraindicated for patients with fructose intolerance.

What should I know about interactions with other medicines?

Karazepin (carbamazepine) is known to interact with a significant number of other medications, potentially affecting its own concentration or the concentration and effectiveness of the co-administered drug. This is primarily due to its ability to induce certain liver enzymes (CYP450 system) that accelerate drug metabolism.

It is critical to inform your healthcare provider of all prescription and over-the-counter medicines, vitamins, and herbal products you are currently taking.

Drugs that can have reduced effectiveness by Karazepin:

  • Anticoagulants (e.g., warfarin, direct oral anticoagulants), leading to a higher risk of blood clots.
  • Hormonal Contraceptives (e.g., birth control pills), which can result in treatment failure (unintended pregnancy).
  • Antipsychotics (e.g., quetiapine, aripiprazole) and Tricyclic Antidepressants (TCAs).
  • Other Anticonvulsants (e.g., lamotrigine, clonazepam, topiramate, valproic acid).

Drugs that can increase Karazepin levels (raising toxicity risk):

  • Certain antibiotics (e.g., macrolides like erythromycin, clarithromycin).
  • Certain antifungals (e.g., fluconazole, ketoconazole).
  • Some antidepressants (e.g., nefazodone is contraindicated).

Food and Herbal Interactions

  • Grapefruit and Grapefruit Juice should be avoided as they can significantly increase Karazepin blood levels, raising the risk of side effects.
  • The herbal remedy St. John's Wort can decrease Karazepin's effectiveness and should not be used concurrently.

Consult your doctor for appropriate dose adjustments or alternative treatment options if any of these interactions apply.

Mechanism of Action

How Karazepin Works

Karazepin operates through a precise, multi-level pharmacodynamic mechanism focused on modulating specific signaling dynamics within the central nervous system. The drug initiates its action by engaging in targeted receptor modulation, binding with high affinity to a defined subset of neurotransmitter receptors in neural tissue. This molecular interaction immediately influences cellular communication by either blocking or altering the natural activity of these receptors.

This primary binding action triggers a mechanistic cascade that modifies specific neural pathways. It acts by altering the resulting signal transduction and ion flow across cell membranes. Karazepin modifies the kinetics of overactive or dysregulated signaling sequences, resulting in an alteration of pathway activity within targeted central and peripheral circuits. This influence on fundamental pathways engages mechanisms that regulate systemic physiological responses by reducing the signal magnitude generated by excessive mediator activity and influencing associated feedback loops.

Dosage and Administration Information

Karazepin (Carbamazepine) is administered primarily via the oral route, utilizing forms such as immediate-release (IR) tablets, extended-release (XR) tablets, XR capsules, and an oral suspension. Intravenous (IV) or rectal administration is approved only for temporary replacement use, typically limited to a period of seven days, when oral intake is not possible.

Standard Administration Protocol

The official usage protocol mandates a slow, gradual increase in dosage, known as titration, rather than starting at the final maintenance dose. For conditions like epilepsy and Bipolar I Disorder, the typical initial adult dose is 200 mg twice daily, with the maximum recommended daily dose not exceeding 1600 mg. For trigeminal neuralgia, the starting adult dose is lower, at 100 mg twice daily, with a maximum daily limit of 1200 mg.

Timing and Form-Specific Instructions

Dosing frequency requires divided daily administration; XR forms are usually taken twice daily, while IR forms may be taken up to four times daily. A key instructional constraint relates to food intake: IR forms should be taken with meals, while XR capsules may be taken with or without food. To ensure the medication's controlled release properties, extended-release tablets must not be crushed or chewed. In cases of a missed dose, the patient instruction is to take the dose when remembered, but not to double the dose if the next scheduled administration is imminent. Furthermore, older adults being treated for trigeminal neuralgia are often initiated on a lower starting dose.

Recent Clinical Evidence

Karazepin: Recent Clinical Evidence

Research examining Karazepin was the subject of studies in clinical contexts characterized by acute or disruptive episodes, such as focal (partial onset) seizures and generalized tonic-clonic seizures. The evidence landscape primarily consists of numerous Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that have explored its use both as a sole treatment and in parallel with other treatments. These studies focused on outcomes related to systemic or functional imbalance, where researchers monitored measures like the proportion of patients achieving seizure freedom and the reduction in seizure frequency. Findings from comparative evidence data show patterns related to measured outcomes that were similar to those observed with certain other treatments studied in parallel.

Karazepin was the subject of research exploring short-term symptom changes in conditions characterized by fluctuating or episodic manifestations, specifically trigeminal neuralgia. The evidence base includes placebo-controlled RCTs and systematic reviews focused on outcomes related to physical discomfort. Researchers specifically monitored patient-reported outcomes describing perceived discomfort and the frequency of painful episodes. Findings from these controlled trials reported measurements of pain intensity scores that differed between the Karazepin group and the placebo group over short treatment periods.

For Bipolar I Disorder, research was the subject of evaluation in conditions involving periods of heightened symptoms, specifically acute manic and mixed episodes. Randomized, Double-blind, Placebo-controlled Trials explored changes in symptom intensity using standardized tools like the Young Mania Rating Scale (YMRS). Findings from RCTs data show patterns related to standardized mania symptom scores where the mean change from baseline differed between the Karazepin group and the placebo group at the study endpoint.

Research has also examined observed long-term patterns of use and evidence in specific patient groups, such as children and older adults. However, a review of the evidence data show patterns related to consistency and completeness. Certainty remains low regarding long-term maintenance treatment for Bipolar Disorder and comprehensive comparative data against all newer anti-seizure medications. Data for certain groups remain insufficient, and long-term effects are not fully established through highly controlled trials.

How should Karazepin be stored and disposed of?

Karazepin (Carbamazepine) must be stored according to official regulatory requirements to maintain its stability and effectiveness.

Official Storage Conditions

The medicine should be stored at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and light. It is mandatory to keep the medicine in its original container and ensure the container remains tightly closed.

  • Handling Restriction: The Oral Suspension formulation must not be frozen.
  • Child Safety: Karazepin must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Karazepin must not be thrown away via household waste or flushed down the toilet, as prohibited by regulatory documents. Disposal must follow procedures outlined by a pharmacist or local waste authority to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTurkey

Equivalent of Karazepin found in:

A-Z Index: